Shukui Qin
YOU?
Author Swipe
View article: Chinese expert consensus on diagnosis and treatment of small gastrointestinal stromal tumors (2025 edition)
Chinese expert consensus on diagnosis and treatment of small gastrointestinal stromal tumors (2025 edition) Open
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, with malignant potential ranging from very low risk to high risk. Small GISTs, defined as those with measuring <2 cm in greatest …
View article: The global, regional, and national burdens of urticaria in 204 countries and territories from 1990 to 2021: An observational epidemiological study based on the Global Burden of Disease Study 2021
The global, regional, and national burdens of urticaria in 204 countries and territories from 1990 to 2021: An observational epidemiological study based on the Global Burden of Disease Study 2021 Open
Urticaria is a common dermatological condition with significant regional and national variations in incidence, prevalence, and disease burden. This study examined trends in these factors, along with disability-adjusted life years (DALYs), …
View article: Supplementary Methods S1 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Methods S1 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study Open
Supplementary Methods S1. Supplementary details of study design, patient enrollment, statistical analysis and sample size calculation.
View article: Supplementary Figure S4 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Figure S4 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study Open
Supplementary Figure S4. The PFS and OS curves.
View article: Data from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Data from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study Open
Purpose:The study was conducted to evaluate porustobart (HBM4003), a novel anti–cytotoxic T lymphocyte–associated protein 4 monoclonal antibody, combined with toripalimab as second-line therapy in advanced hepatocellular carcinoma (HCC).Pa…
View article: Supplementary Figure S1 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Figure S1 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study Open
Supplementary Figure S1. Patients enrollment flowchart.
View article: Supplementary Table S2 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Table S2 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study Open
Supplementary Table S2. Safety data.
View article: Supplementary Figure S2 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Figure S2 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study Open
Supplementary Figure S2. Changes in peripheral blood cytokines before and after treatment.
View article: Safety of fruquintinib in Chinese patients with colorectal cancer: an age subgroup analysis from a phase IV real-world clinical practice study
Safety of fruquintinib in Chinese patients with colorectal cancer: an age subgroup analysis from a phase IV real-world clinical practice study Open
Background: Colorectal cancer (CRC) is increasingly prevalent among young adults (<50 years) in China, a demographic that has been historically underrepresented in clinical studies. While most patients with CRC are aged ⩾65 years, this age…
View article: Supplementary Figure S3 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Figure S3 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study Open
Supplementary Figure S3. Exploration of the association between the tumor immune microenvironment and efficacy.
View article: Supplementary Table S1 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Table S1 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study Open
Supplementary Table S1. Representativeness of Study Participants.
View article: Supplementary Table S3 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Supplementary Table S3 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study Open
Supplementary Table S3. Density of various immune cells and their ratio to CD8+ cells as revealed by multiplex immunofluorescence.
View article: Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO
Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO Open
Clinically meaningful efficacy of fruquintinib was maintained in a global patient population with less pretreated mCRC than the FRESCO-2 ITT population, with no new safety signals, demonstrating efficacy regardless of prior treatment lines.
View article: Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study Open
PURPOSE The phase III randomized open-label LEAP-015 study (ClinicalTrials.gov identifier: NCT04662710 ) evaluated first-line lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy for advanced metastatic gastroesophageal adeno…
View article: Hotspots and trends in gastric cancer stem cell research: a visualization and bibliometric analysis
Hotspots and trends in gastric cancer stem cell research: a visualization and bibliometric analysis Open
Background Gastric cancer (GC) is a type of malignant tumor that seriously endangers human health. As the understanding of the mechanisms underlying gastric cancer deepens, in recent years, investigations on gastric cancer stem cells (GCSC…
View article: StreamDCIM: A Tile-based Streaming Digital CIM Accelerator with Mixed-stationary Cross-forwarding Dataflow for Multimodal Transformer
StreamDCIM: A Tile-based Streaming Digital CIM Accelerator with Mixed-stationary Cross-forwarding Dataflow for Multimodal Transformer Open
Multimodal Transformers are emerging artificial intelligence (AI) models designed to process a mixture of signals from diverse modalities. Digital computing-in-memory (CIM) architectures are considered promising for achieving high efficien…